Company news

Immutep Ltd news in 2022

Immutep Ltd's news releases, calls and decks from 2022, newest first.

View company

Update on MBC trial design following successful FDA meeting

December 23, 2022

Commercial Scale in Manufacturing of Efti Achieved

December 7, 2022

GMP Manufacturing Process Developed for IMP761 LAG-3 Agonist

December 5, 2022

Immutep enters 2nd collaboration with Pfizer and Merck KGaA

November 28, 2022

Immutep receives A$1 million R&D Tax Incentive

November 13, 2022

Immutep Webcast to discuss clinical data presented at SITC

November 10, 2022

New Patents Granted in Japan and South Korea for Efti

November 9, 2022

Late Breaking Abstract accepted for SITC Oral Presentation

November 2, 2022

Independent DMC recommends to continue TACTI-003 as planned

October 25, 2022

Abstracts accepted for Presentation at SITC 2022

October 5, 2022

Fast Track granted by US FDA for Efti in 1st line NSCLC

October 3, 2022

Immutep Receives A$2.7 million R&D French Tax Incentive

September 22, 2022

Clinical Development Update for Eftilagimod Alpha

September 13, 2022

New investigator-initiated ph2 trial in Soft Tissue Sarcoma

September 5, 2022

Appendix 4E & 2022 Full Year Statutory Accounts

August 31, 2022

Japanese Patent Grant for efti, soluble LAG-3 with anti-PD-1

August 30, 2022

TACTI-002 2nd line lung cancer data presented at 2022 WCLC

July 31, 2022

Quarterly Activities/Appendix 4C Cash Flow Report

July 28, 2022

Immutep granted Japanese Patent for IMP761

July 5, 2022

Webcast slides for 1st line NSCLC data from TACTI-002 trial

June 5, 2022

Immutep announces publication of ASCO 2022 abstracts

May 26, 2022

New & significant data from AIPAC phase 2b trial in MBC

May 4, 2022

Immutep to announce new TACTI-002 data at ASCO 2022

April 27, 2022

Efti with Keytruda shows encouraging activity in lung cancer

March 29, 2022

Immutep announces publication of ELCC 2022 abstract

March 23, 2022

Japanese patent granted for LAG-3 antibody LAG525

March 18, 2022

Immutep receives FDA feedback for Efti development in MBC

March 9, 2022

Australian Patent Granted for Efti with PD-1 Inhibitors

February 11, 2022

Decks in 2022